Mitoxantrone (NSC-301739) 2HCl

For research use only. Not for use in humans.

目录号:S2485 中文名称:米托蒽醌

Mitoxantrone (NSC-301739) 2HCl Chemical Structure

CAS No. 70476-82-3

Mitoxantrone 2HCl (NSC-301739) 是Mitoxantrone的盐酸盐形式。Mitoxantrone 是一种 type II topoisomeraseprotein kinase C (PKC)的抑制剂,对于PKC的IC50值为 8.5 μM。Mitoxantrone 可抑制MCF-7/wt cells的细胞增殖,对应的IC50值为0.42 μM。Mitoxantrone 还可诱导细胞凋亡。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 745.02 现货
RMB 568.06 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Mitoxantrone (NSC-301739) 2HCl发表文献33篇:

产品安全说明书

Topoisomerase抑制剂选择性比较

生物活性

产品描述 Mitoxantrone 2HCl (NSC-301739) 是Mitoxantrone的盐酸盐形式。Mitoxantrone 是一种 type II topoisomeraseprotein kinase C (PKC)的抑制剂,对于PKC的IC50值为 8.5 μM。Mitoxantrone 可抑制MCF-7/wt cells的细胞增殖,对应的IC50值为0.42 μM。Mitoxantrone 还可诱导细胞凋亡。
靶点
Topoisomerase II [1]
()
PKC [7]
(Cell-free assay)
8.5 μM
体外研究

Methotrexate通过主动转运或易化扩散进入细胞和在细胞内经过多聚谷氨酸化后,会抑制二氢叶酸还原酶和二氢叶酸转化为四氢叶酸。Methotrexate抑制嘌呤和嘧啶的从头合成,多胺的形成以及DNA、RNA、磷脂和蛋白质的转甲基作用。Methotrexate也会抑制胸苷酸合成酶,从而使细胞内胸苷酸不足,这可能导致抗增殖的细胞毒性作用。酶促反应被Methotrexate的多聚谷氨酸化最有效抑制的是5-氨基-4-甲酰胺咪唑核糖核苷酸(AICAR)转化为甲酰-AICAR,反应被AICAR甲酰基转移酶抑制,因此导致细胞内AICAR的积累和腺苷释放。[1] Methotrexate增加成纤维细胞、内皮细胞和其他细胞中腺苷的释放。Methotrexate显著增加腺苷的释放,在成纤维细胞中从总嘌呤释放(EC50, 1 nM)的4%到31%,在内皮细胞中,从24%到42%。通过暴露到受激的(fMet-Leu-Phe在0.1 μM下)中性粒细胞,Methotrexate增强的腺苷释放,在成纤维细胞中进一步增加到总嘌呤释放的51% (EC50, 6 nM),在内皮细胞中增加到58%。[2] Methotrexate抑制免疫细胞趋药性。Methotrexate (2.5微克/毫升)治疗迅速降低多形核中性粒细胞PMNs的体外趋化反应。[3] Methotrexate抑制炎症细胞因子的活性。在体外实验中,5 nM Methotrexate抑制IL-1活性,从而抑制血管内皮细胞增殖。[4] Methotrexate诱导细胞凋亡。来自人类外周血液的T细胞体外活化后,Methotrexate (0.1-10 μM)会诱导其细胞凋亡。[5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
L1210 cell NUDE[GVZS3m2b4TvfIlkcXS7IHHzd4F6 M3vpU|Q5KGh? M2CxWmN6fG:2b4jpZ{Bxd3SnbnP5JJJmeXWrcnXkJJRwKGmwaHnibZQhVDF{MUCgZ4VtdCCpcn;3eIgh[nliNUClJIFnfGW{IHPlcIwh\HK3ZzDjc451[WO2IH\vdkA1QCCqcoOsJGlEPTB;NHWtNFUh|ryP M2PldFk{PzF{NEC=
HL60 cells NX7ne2VjS3m2b4TvfIlkcXS7IHHzd4F6 MX[0PEBp MmfxR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGw3OCClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBIUTVyPUCuN|Mh|ryP MmHRNVc6PjJyMki=
MDA435/LCC6 cells MYDQdo9tcW[ncnH0bY9vKGG|c3H5 NYrielRESW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBOTEF2M{WvUGNEPiClZXzsd{BjgSCHTFnTRUwhUUN3ME2wMlM2KG6P NYDlU3o6OTdzNUS1NFU>
A2780-cell MmroS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFW5UlFEd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgRVI4QDBvY3XscEBoem:5dHigZpkhPTBnLDDJR|UxRTBwNUWgcm0> NWPPZohuQTdyM{S3NS=>
G-361 cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MX3DfZRwfG:6aXOgdI91\W6leTDy[ZF2cXKnZDD0c{BqdmirYnn0JGcuOzZzIHPlcIwh\3Kxd4ToJIJ6KDVyJTygTWM2OD1yLk[1JI5O MWC5N|cyOjRy
human HL60 cells M4LYSHBzd2yrZnXyZZRqd25iYYPzZZk> M3L5UlczKGh? NITlSVBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OD1{LkWgcm0> NH7aWlEzOjl2NEGyNS=>
human K562 cells NV32ZW1IS3m2b4TvfIlkcXS7IHHzd4F6 NIn5T3g2KGSjeYO= NXS3NJgyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUzV4MjDj[YxteyCjZoTldkA2KGSjeYOgZpkhYFSWIHHzd4F6NCCLQ{WwQVIvPiCwTR?= NX[xbndGOThyN{[xOFA>
CH1 cell MlrBR5l1d3SxeHnjbZR6KGG|c3H5 NYOwVGFWS3m2b4TvfIlkKHCxdHXuZ5khemWzdXny[YQhfG9iaX7obYJqfCCFSEGgZ4VtdCCpcn;3eIgh[nliNUClMEBKSzVyPUKuOlUhdk1? NW\wfWVWQTN5MUK0NC=>
MES-SA cells NFnUUmVRem:uaX\ldoF1cW:wIHHzd4F6 NXXDeYNrPzJiaB?= MmCwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDNSXMuW0FiY3XscJMh[nliTWTUJIF{e2G7IHHmeIVzKDd{IHjyd{whUUN3ME2zJI5O MWSxOlgzPDd3MR?=
A549 cells MnjzSpVv[3Srb36gZZN{[Xl? NXXxXXJSSWO2aY\peJkh[WejaX7zeEBCPTR7IHPhcoNmeiClZXzsJIxqdmVuIFnDOVA:Oy5zIH7N MmDaPFk3ODV3OB?=
LoVo cells MYnDfZRwfG:6aXPpeJkh[XO|YYm= NHTsUWwyPDRiaB?= MU\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMc3ZwKGOjbnPldkBk\WyuIHzpcoUhf2G|IHTleIVzdWmwZXSgZYZ1\XJiMUS0JIhzNCCLQ{WwQVMvOyCwTR?= NYXZ[3NpOTV2NU[yOlg>
P388 cells NXXVWVRJWHKxbHnm[ZJifGmxbjDhd5NigQ>? MlrORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDQN|g5KGOnbHzzJIJ6KEWOSWPBMEBKSzVyPUSuN{BvVQ>? MXKxO|E2PDVyNR?=
human Daudi cells M{TpZnBzd2yrZnXyZZRqd25iYYPzZZk> M362dlczKGh? NInUOW5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFTheYRqKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;NTDuUS=> NVXOWVc3OjV7OUi1NFQ>
SKOV-3 cell MUDDfZRwfG:6aXPpeJkh[XO|YYm= M2XzSmN6fG:2b4jpZ{Bxd3SnbnP5JJJmeXWrcnXkJJRwKGmwaHnibZQhW0uRVj2zJINmdGxiZ4Lve5RpKDVyJTygTWM2OD13LkOgcm0> MXW5N|cyOjRy
OVCAR-3 cell MmfXSpVv[3Srb36gZZN{[Xl? M2XmRmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIH;2ZZJq[W5iT2\DRXIuOyClZXzsJIxqdmW|LDDJR|UxRTVwODDuUS=> NYK5WVNEQDl4MEW1PC=>
human MES-SA cells NHLkPYFRem:uaX\ldoF1cW:wIHHzd4F6 MnLWO|IhcA>? M2PYd2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVXTMXNCKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;NjDuUS=> MoTKNlU6QTh3MES=
PC3 cancer cell NIL3dZpEgXSxdH;4bYNqfHliYYPzZZk> MV6xOFQhcA>? NUT0RnJvS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN|IHPhcoNmeiClZXzsJIxqdmVid3HzJIRmfGW{bXnu[YQh[W[2ZYKgNVQ1KGi{LDDJR|UxRTdibl2= NFjsXoMyPTR3NkK2PC=>
MXF7 breast cell NWrTcXR{TnWwY4Tpc44h[XO|YYm= MW\BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCvYX3tZZJ6KGOjcnPpco9u[SC|ZX7zbZRqfmViTWjGO{BjemWjc4SgZ4VtdCCuaX7lMEBKSzVyPUiuO{BvVQ>? NXy5c25KQDl4MEW1PC=>
HT-29 cell M2HBSWN6fG:2b4jpZ4l1gSCjc4PhfS=> NX7UdFBMOTR2IHi= M3;rU2N6fG:2b4jpZ{Bxd3SnbnP5JJJmeXWrcnXkJJRwKGmwaHnibZQhUFRvMkmgZ4VtdCCpcn;3eIgh[nliNUClJIFnfGW{IHPlcIwh\HK3ZzDjc451[WO2IH\vdkAyPDRiaILzMEBKSzV;MD6wNUDPxE1? NUTWclNzQTN5MUK0NC=>
HEK293 cells MV;DfZRwfG:6aXPpeJkh[XO|YYm= NHPrTlk4OiCq NXLCfIl6S3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNUDPxE1? NEHEcHAzPDZzMUi5Ny=>
MKN45 cells M4nodGN6fG:2b4jpZ4l1gSCjc4PhfS=> MWOxOFQhcA>? NEO3ZZdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOU052NTDjZY5k\XJiY3XscEBtcW6nIIfhd{Bl\XSncn3pcoVlKGGodHXyJFE1PCCqcjygTWM2OD1yLkCxNkDPxE1? NFn5e4EyPTR3NkK2PC=>
MES-SA cells MWfDfZRwfG:6aXPpeJkh[XO|YYm= M4fTXlczKGh? MVnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSXMuW0FiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlAyOiEQvF2= NIKz[VAzOTR2NEKwOS=>
FM3 cells MYHQdo9tcW[ncnH0bY9vKGG|c3H5 Mnj5O|IhcA>? NFLLbmdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF\NN{Bk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMEGzJO69VQ>? MV[yOVk6QDVyNB?=
MCF-7 cells NFf6d25Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWLmcIhJUW6qaXLpeI9zgSCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJJR2dW:{IHPlcIwhdGmwZTDNR2YuPyCkcnXhd5Qh[WSnbn;jZZJkcW6xbXGsJGlEPTB;MD6wNkDPxE1? M2TpPVc5PTN|NEW=
human small-cell lung cancer M3;ScGN6fG:2b4jpZ4l1gSCjc4PhfS=> M1rqZ2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJNu[WyuLXPlcIwhdHWwZzDjZY5k\XJiKGPDUGMqNCCLQ{WwQVAvODJizszN MlnPPFI2QDh|NR?=
human HCT116 cells M4LpRmN6fG:2b4jpZ4l1gSCjc4PhfS=> MY[3NkBp NXn1ZllIS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMkKg{txO M4THW|IyPDR2MkC1
human HCT116 cells M3rtZnBzd2yrZnXyZZRqd25iYYPzZZk> M1\JcVczKGh? MmPPRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCyOUDPxE1? NXrkdYdHOjV7OUi1NFQ>
NCI-H460 cells NWXoRYVuS3m2b4TvfIlkcXS7IHHzd4F6 NILWVZg1QCCq NV;MS5M3S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkOLLVi0OlAh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IILld4F7fXKrbjDkfYUh[XO|YYmsJGVEPTB;MD6wN{DPxE1? M{\MSFI{QTh6M{Wx
CCRF-CEM cells M17s[mN6fG:2b4jpZ4l1gSCjc4PhfS=> MXS0PEBp M{nJWGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNEWkZvQ1XNJINmdGy|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSClZXzseIl1\XJvYnz1[UBie3OjeTygTWM2OD1yLkCzOkDPxE1? NGrjOY4zOjV6Mkm5NS=>
HeLa cells MY\Qdo9tcW[ncnH0bY9vKGG|c3H5 MlH1O|IhcA>? NV;3T4ZQSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wOFQh|ryP MnrsNlU6QTh3MES=
NCI60 cells Mn7sSpVv[3Srb36gZZN{[Xl? MkO0OFghcA>? M12zTGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTVYxKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO|YYmsJGdKPTB;NEeuPFYhdk1? NEnQSIkyQDdzNUe4Oi=>
UACC375 cell NHf0SJhHfW6ldHnvckBie3OjeR?= MlXrRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5ibXXsZY5wdWFiVVHDR|M4PSClZXzsJIxqdmVuIFnDOVA:OC5yNEig{txO MWC4PVYxPTV6
HT1080 cell NYnOOGFYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGfZVVRKdmirYnn0c5J6KGGldHn2bZR6KGGpYXnud5QhcHWvYX6geJVud3JiY3XscEBtcW6nIFjUNVA5OCxiSVO1NF0xNjB4NjFOwG0> Mmn4O|g2OzN2NR?=
MES-SA/Dx5 cells NYroVoVYWHKxbHnm[ZJifGmxbjDhd5NigQ>? MUC3NkBp MnPSRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPRWOtV2EwTHh3IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xPzNizszN NUH4UIw2OjV7OUi1NFQ>
SF268 cells MULQdo9tcW[ncnH0bY9vKGG|c3H5 MlLROFghcA>? M4\NRmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1[yOlgh[2WubIOgZYZ1\XJiNEigbJJ{NCCHQ{WwQVAvOzJizszN MkS3NlM{QTV4NU[=
KB/HeLa cells MYXQdo9tcW[ncnH0bY9vKGG|c3H5 NF3ldFE1QCCq NHWzTFlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvCM2hmVGFiY3XscJMh[W[2ZYKgOFghcHK|LDDFR|UxRTBwM{[g{txO M1LqfFI{Ozl3NkW2
K562 cells MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1nLeVczKGh? NIfiUXpIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBMPTZ{IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFNibXX0bI9lNCCLQ{WwQVAvPDJizszN M{nPUFE5OjV6NESy
MDA-MB-231 cells MUPQdo9tcW[ncnH0bY9vKGG|c3H5 MnnqO|IhcA>? M3jGUmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTJ|MTDj[YxteyCkeTDXV3QuOSCvZYToc4Qh[W[2ZYKgO|IhcHK|LDDJR|UxRTBwOU[g{txO NFTsXZYyPzN|NUG4PS=>
SF268 cells MlL0R5l1d3SxeHnjbZR6KGG|c3H5 NWDKepNMPDhiaB?= Mnm0R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2YzPjhiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlk4KM7:TR?= M2SyXVE4QTZ{MEK4
HCT116 cells MWTDfZRwfG:6aXPpeJkh[XO|YYm= MoTLR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGK7IF3UWEBie3OjeTygTWM2OD1|Lkm2JO69VQ>? NXT5[ZJLOjB7NUG1PFI>
U937 cells MoPaR5l1d3SxeHnjbZR6KGG|c3H5 NGr5XnFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWQTN5IHPlcIx{KGK7IF3UWEBie3OjeTygTWM2OD14LkKg{txO NET0VY0yQTZzNUmwNC=>
HepG2 cells MkXzVJJwdGmoZYLheIlwdiCjc4PhfS=> MmLmOFghcA>? MX;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OTFwMEWg{txO NYrJSGhkOjR5OUS3OFc>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-ROS1 / ROS1 / p-STAT3 / STAT3 / p-AKT / AKT / p-ERK / ERK; 

PubMed: 30108778     


Mechanism of action of mitoxantrone in HCC78 cells. Immunoblot analysis of p-ROS1, ROS1, p-STAT3, STAT3, p-AKT, AKT, p-ERK, ERK and GAPDH in HCC78 cells, cells were harvested after treatment with mitoxantrone for 48 h.

30108778
Growth inhibition assay
Cell number; 

PubMed: 24349321     


LNCaP 104-S, 104- R1, 104-R2, PC-3, and DU-145 cells were treated with increasing concentrations of mitoxantrone for 72 hrs. Relative cell number of LNCaP cells was determined by Hoechst dye 33258-based 96-well proliferation assay. Cell numbers were normalized to control (dimethylsulfoxide) of each cell line. Triple asterisks (***) represent statistically significant difference p < 0.001between the treated group and the control group.

24349321
体内研究

Methotrexate显示出体内抗炎作用。在小鼠气囊炎模型中,Methotrexate以剂量依赖的方式使角叉菜胶处理过的空气袋中聚集的白血球数量减少到60% (IC50 = 0.08 毫克/千克/周)。Methotrexate (0.5 毫克/千克/周)分别增加3倍的淋巴细胞中AICAR浓度,和2倍的炎性渗出物中腺苷浓度。[6]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 DMSO 89 mg/mL (172.01 mM)
Water 89 mg/mL (172.01 mM)
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
Saline
30 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 517.4
化学式

C22H29ClN4O6.2HCl

CAS号 70476-82-3
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04330820 Recruiting Drug: Venetoclax Oral Tablet Relapsed Adult AML Technische Universität Dresden|AbbVie April 6 2020 Phase 1|Phase 2
NCT02131688 Unknown status Drug: Mitoxantrone Hydrochloride Liposome Malignant Lymphoma CSPC ZhongQi Pharmaceutical Technology Co. Ltd. May 2013 Phase 1
NCT01701375 Terminated Drug: PD 0332991 Relapsed Acute Leukemia|Refractory Acute Leukemia|High-Risk Myelodysplasia Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|The Leukemia and Lymphoma Society|Pfizer September 2012 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

Topoisomerase Signaling Pathway Map

相关Topoisomerase产品

Tags: 购买Mitoxantrone (NSC-301739) 2HCl | Mitoxantrone (NSC-301739) 2HCl供应商 | 采购Mitoxantrone (NSC-301739) 2HCl | Mitoxantrone (NSC-301739) 2HCl价格 | Mitoxantrone (NSC-301739) 2HCl生产 | 订购Mitoxantrone (NSC-301739) 2HCl | Mitoxantrone (NSC-301739) 2HCl代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID